DHCG, Porton Advanced Partner To Accelerate Cell, Gene Therapies Development
KUALA LUMPUR, April 28 (Bernama) -- Dark Horse Consulting Group (DHCG) has signed a memorandum of understanding (MoU) with Porton Advanced to establish a strategic collaboration aimed at accelerating the development and clinical translation of cell and gene therapies globally.
Together, the two organisations will offer client companies a cost-effective and rapid pathway into clinical-stage manufacturing, with particular emphasis on enabling investigator-initiated trials (IITs) in China.
DHCG Founder and Chief Executive Officer (CEO), Anthony Davies said the MoU with Porton Advanced represents a streamlined pathway for its client partners interested in undertaking IITs in China.
“For programmes targeting the Chinese market, particularly those pursuing IITs, having a trusted, proven manufacturing partner with NMPA-aligned quality systems will provide DHCG clients with decreased times to first-in-human, and rapid tech transfer and manufacture,” he said in a statement.
Meanwhile, Porton Advanced CEO, Andrew Chen said the collaboration combines its end-to-end cell and gene therapy contract development and manufacturing organisation (CDMO) capabilities with DHCG’s strategic consulting depth to create a differentiated offering for developers at every stage.
For clients seeking to conduct IITs in China, one of the fastest-growing markets for advanced therapies, the collaboration addresses challenges at the intersection of international regulatory strategy and local manufacturing.
Porton Advanced holds 24 IND clearances across the NMPA and FDA and has supported more than 30 IITs to date, while DHCG brings regulatory, CMC, clinical and quality expertise to guide programme design and execution.
By combining their capabilities under a formal framework, the partners aim to accelerate development timelines, improve efficiency and reduce delays in IIT initiation.
DHCG is a leader in strategic and operational biotherapeutics consulting, with offices across North America, Europe and Asia Pacific, while Porton Advanced is a CDMO specialising in advanced therapy medicinal products.
-- BERNAMA